Singapore markets closed

APx Acquisition Corp. I (APXI)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
11.57-0.01 (-0.09%)
At close: 04:00PM EDT
12.16 +0.59 (+5.10%)
After hours: 05:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.58
Open11.57
Bid0.00 x 0
Ask0.00 x 0
Day's range11.57 - 11.58
52-week range9.86 - 11.58
Volume2,113
Avg. volume9,087
Market cap114.66M
Beta (5Y monthly)0.01
PE ratio (TTM)28.92
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    APX Acquisition Corp. I Reports 10-K Delinquency Notice

    APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the quarter ended March 31

  • PR Newswire

    APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform

    APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subjec

  • PR Newswire

    APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q

    APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule